Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

In “Lilly,” writer-director Rachel Feldman follows the era-defining work of one such everyday woman: trailblazer Lilly Ledbetter, a pioneer from humble beginnings who took her employer ...

Despite the controversy around Sam Levinson‘s The Idol, Lily-Rose Depp has nothing but praise about her time working with the show’s creator. The actress recently defended Levinson after he ...

BELGRADE, Serbia — Serbia's striking university students on Monday launched a 24-hour blockade of a key traffic intersection in the capital Belgrade, stepping up pressure on the populist ...

Lily Allen reportedly discovered her husband had a secret dating app profile late last year (Picture: Dave Benett/Getty Images for Harper’s Bazaar) New reports have claimed Lily Allen only went ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Senior equity analysts at StockNews.com upgraded Eli Lilly (LLY, Financial) stock from 'hold' to 'buy' as its stock has shifted positively. Analysts say the upgrade is a sign of increased ...

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...